legislation: 115-hr-7369
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| bill_id | congress | bill_type | bill_number | title | policy_area | introduced_date | latest_action_date | latest_action_text | origin_chamber | sponsor_name | sponsor_state | sponsor_party | sponsor_bioguide_id | cosponsor_count | summary_text | update_date | url |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115-hr-7369 | 115 | hr | 7369 | DEA Notification Act of 2018 | Health | 2018-12-20 | 2018-12-20 | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | House | Rep. Bilirakis, Gus M. [R-FL-12] | FL | R | B001257 | 1 | DEA Notification Act of 2018 This bill requires the Centers for Medicare & Medicaid Services to notify the Drug Enforcement Administration (DEA) of providers or suppliers that are prohibited from participating in Medicare due to improper prescriptions of controlled substances, and to recommend that the DEA consider revoking certain controlled substance registrations or waivers held by such providers or suppliers. | 2023-01-11T13:40:45Z |